This event has passed.

Tofersen FDA Advisory Committee

Name: Tofersen FDA Advisory Committee
Start: 2023-03-22T09:15:00-04:00
End: 2023-03-22T18:00:00-04:00

March 22, 2023 @ 9:15 am - 6:00 pm EDT

Agenda

The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform. The committee will discuss new drug application (NDA) 215887, for tofersen (BIIB067) intrathecal injection, submitted by Biogen Inc., for the treatment of amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene.

Details

Date:: March 22, 2023
Time:: 9:15 am - 6:00 pm EDT
Website:: https://www.fda.gov/advisory-committees/advisory-committee-calendar/updated-meeting-time-and-public-participation-information-march-22-2023-meeting-peripheral-and